medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2020-2-97-102medsovet-5526Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYПрименение эторикоксиба в терапии остеоартритаEtoricoxib in the treatment of osteoarthritishttps://orcid.org/0000-0003-1721-2061АникинС. Г.AnikinS. G.

Аникин Сергей Германович, кандидат медицинских наук, старший научный сотрудник

115522, Москва, Каширское шоссе, д. 34А

Sergey G. Anikin, Cand. of Sci. (Med.), Senior Researcher

34A, Kashirskoe shosse, Moscow, 115522, Russia

artos2000@yandex.ruhttps://orcid.org/0000-0001-7017-0898АлексееваЛ. И.AlekseevaL. I.

Алексеева Людмила Ивановна, доктор медицинских наук, заведующая лабораторией

115522, Москва, Каширское шоссе, д. 34А

Lyudmila I. Alekseeva, Dr. of Sci. (Med.), Head of Laboratory

34A, Kashirskoe shosse, Moscow, 115522, Russia

dr.alekseeva@gmail.comНаучно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2020030320200297102Copyright © Аникин С.Г., Алексеева Л.И., 20202020Аникин С.Г., Алексеева Л.И.Anikin S.G., Alekseeva L.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5526

Остеоартрит (ОА) является одним из самых распространенных заболеваний скелетно-мышечной системы. Клинически ОА проявляется болью механического характера, припухлостью и непродолжительной утренней скованностью. Согласно эпидемиологическим исследованиям, у лиц, испытывающих хроническую боль, около трети хронической умеренной и сильной боли приходится именно на случаи ОА. В настоящее время рассматривается мультифакторная модель ОА, согласно которой это заболевание является результатом взаимодействия различных генетических, биологических, механических и обменных факторов. По современным представлениям, воспалительные реакции при ОА играют ведущую роль в развитии и прогрессировании этого заболевания. У пациентов с ОА при гистологических исследованиях синовиальной оболочки пораженного сустава выявляется целый ряд изменений, свойственный хроническому воспалению. В сыворотке крови, синовиальной жидкости и в тканях сустава может определяться повышение уровня некоторых провоспалительных цитокинов и снижение противовоспалительных цитокинов, а также развитие адаптивных иммунных клеточных реакций в тканях сустава, наблюдаемых и при других ревматических заболеваниях.

Благодаря высокой эффективности нестероидные противовоспалительные препараты (НПВП) заняли прочное место в терапии ОА. Во всех современных руководствах НПВП являются препаратами выбора уже на самых первых этапах лечения ОА в виде локальных или пероральных форм. Эторикоксиб является селективным ингибитором циклооксигеназы 2 (ЦОГ-2) и применяется для лечения ОА и других ревматических заболеваний. В статье обсуждаются возможности применения эторикоксиба у лиц с ОА. Представлен обзор клинических исследований эффективности и безопасности эторикоксиба у больных ОА.

Osteoarthritis (OA) is one of the most common diseases of the musculoskeletal system.

The main symptoms of osteoarthritis are pain, stiffness, joint swelling. According to epidemiological studies, about one-third of the chronic moderate and severe pain is associated with OA. Currently, OA is considered as a multifactorial disease resulting from the interaction of various genetic, biological, mechanical, and metabolic factors. Inflammation plays a central role in development and progression of ОА. In patients with OA, histological studies of the synovial membrane detected signs of chronic inflammation. The level of some proinflammatory cytokines may increased and the level of anti-inflammatory cytokines may decreased in blood serum, synovial fluid and joint tissue. Also, adaptive immune cell responses are detected in the joint tissues in patients of OA. Due to its high effectiveness, non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in OA. Oral or local forms of NSAIDs are the drugs of choice in the initial stages of therapy in all guidelines. Etoricoxib is a selective inhibitor of cyclooxygenase 2 (COX-2) and is used for the treatment of OA and other rheumatic diseases. The article discusses the use of etoricoxib in patients with OA.

остеоартритнестероидные противовоспалительные препаратыэторикоксибклиническая эффективностьбезопасностьosteoarthritisnon-steroidal anti-inflammatory drugsclinical efficacysafetyetoricoxibReferencesBreivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. EJP. 2006;10(4):287–333. doi: 10.1016/j. ejpain.2005.06.009.Breivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. EJP. 2006;10(4):287–333. doi: 10.1016/j.ejpain.2005.06.009.Фоломеева О.М., Амирджанова В.Н., Якушева О.Е. Анализ структуры XIII класса болезней. Росcийская Ревматология. 1998;(1):2–7. Folomeeva O.M., Amirdzhanova V.N., Yakusheva O.E. Analysis of class XIII diseases structure. Rossiyskaya Revmatologiya = Russian Rheumatology. 1998;(1):2–7. (In Russ.)Фоломеева О.М., Амирджанова В.Н., Якушева О.Е. Анализ структуры XIII класса болезней. Росcийская Ревматология. 1998;(1):2–7. Folomeeva O.M., Amirdzhanova V.N., Yakusheva O.E. Analysis of class XIII diseases structure. Rossiyskaya Revmatologiya = Russian Rheumatology. 1998;(1):2–7. (In Russ.)Saase van J.L., Romunde van L.K., Cats A., Vandenbroucke J.P., Valkenburg H.A. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis. 1989;48(4):271–80. doi: 10.1136/ard.48.4.271.Saase van J.L., Romunde van L.K., Cats A., Vandenbroucke J.P., Valkenburg H.A. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis. 1989;48(4):271–80. doi: 10.1136/ard.48.4.271.Peat G., McCarney R., Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001;60(2):91–97. doi: 10.1136/ard.60.2.91.Peat G., McCarney R., Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001;60(2):91–97. doi: 10.1136/ard.60.2.91.Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471–478. doi: 10.1097/BOR.0b013e328349c2b1.Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471–478. doi: 10.1097/BOR.0b013e328349c2b1.Roemer F.W., Kassim J.M., Guermazi A., Thomas M., Kiran A., Keen R. et al. Anatomical distribution of synovitis in knee osteoarthritis and its association with joint effusion assessed on non-enhanced and contrast-enhanced MRI. Osteoarthritis Cartilage. 2010;18(10):1269–1274. doi: 10.1016/j.joca.2010.07.008.Roemer F.W., Kassim J.M., Guermazi A., Thomas M., Kiran A., Keen R. et al. Anatomical distribution of synovitis in knee osteoarthritis and its association with joint effusion assessed on non-enhanced and contrast-enhanced MRI. Osteoarthritis Cartilage. 2010;18(10):1269–1274. doi: 10.1016/j.joca.2010.07.008.Lindblad S., Hedfors E. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. Arthritis Rheum. 1987;30(10):1081–1088. doi: 10.1002/art.1780301001.Lindblad S., Hedfors E. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. Arthritis Rheum. 1987;30(10):1081–1088. doi: 10.1002/art.1780301001.Revell P.A., Mayston V., Lalor P., Mapp P. The synovial membrane in osteoarthritis: a histological study including the characterisation of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodies. Ann Rheum Dis. 1988;47(7):300–307. doi: 10.1136/ard.47.4.300.Revell P.A., Mayston V., Lalor P., Mapp P. The synovial membrane in osteoarthritis: a histological study including the characterisation of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodies. Ann Rheum Dis. 1988;47(7):300–307. doi: 10.1136/ard.47.4.300.Scanzello C.R. Role of low-grade inflammation in osteoarthritis. Curr Opin Rheumatol. 2017; 29(1):79–85. doi: 10.1097/BOR.0000000000000353.Scanzello C.R. Role of low-grade inflammation in osteoarthritis. Curr Opin Rheumatol. 2017; 29(1):79–85. doi: 10.1097/BOR.0000000000000353.Altobelli E., Angeletti P.M., Piccolo D., De Angelis R. Synovial fluid and serum concentrations of inflammatory markers in rheumatoid arthritis, psoriatic arthritis and osteoarthitis: A Systematic Review. Curr Rheumatol Rev. 2017;13(3):170–179. doi: 10.2174/157339 7113666170427125918.Altobelli E., Angeletti P.M., Piccolo D., De Angelis R. Synovial fluid and serum concentrations of inflammatory markers in rheumatoid arthritis, psoriatic arthritis and osteoarthitis: A Systematic Review. Curr Rheumatol Rev. 2017;13(3):170–179. doi: 10.2174/1573397113666170427125918.Smith M.D., Triantafillou S., Parker A., Youssef P.P., Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24(2):365–371. Available at: https://pubmed.ncbi.nlm.nih. gov/9034998-synovial-membrane-inflammation-and-cytokine-production-in-patientswith-early-osteoarthritis/Smith M.D., Triantafillou S., Parker A., Youssef P.P., Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol. 1997;24(2):365–371. Available at: https://pubmed.ncbi.nlm.nih.gov/9034998-synovial-membrane-inflammation-and-cytokine-production-in-patientswith-early-osteoarthritis/Bannuru R.R., Osani M. C., Vaysbrot E. E., Arden N.K., Bennell K., Bierma-Zeinstra S.M.A. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578– 1589. doi: 10.1016/j.joca.2019.06.011.Bannuru R.R., Osani M. C., Vaysbrot E. E., Arden N.K., Bennell K., Bierma-Zeinstra S.M.A. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578– 1589. doi: 10.1016/j.joca.2019.06.011.Liu P., Gu L., Ren L., Chen J., Li T., Wang X. et al. Intra-articular injection of etoricoxib-loaded PLGA-PEG-PLGA triblock copolymeric nanoparticles attenuates osteoarthritis progression. Am J Transl Res. 2019;11(11):6775–6789. Available at; https://pubmed.ncbi.nlm.nih.gov/31814887-intra-articular-injection-ofetoricoxib-loaded-plga-peg-plga-triblockcopolymeric-nanoparticles-attenuates-osteoarthritis-progression/Liu P., Gu L., Ren L., Chen J., Li T., Wang X. et al. Intra-articular injection of etoricoxib-loaded PLGA-PEG-PLGA triblock copolymeric nanoparticles attenuates osteoarthritis progression. Am J Transl Res. 2019;11(11):6775–6789. Available at; https://pubmed.ncbi.nlm.nih.gov/31814887-intra-articular-injection-ofetoricoxib-loaded-plga-peg-plga-triblockcopolymeric-nanoparticles-attenuates-osteoarthritis-progression/Gottesdiener K., Schnitzer T., Fisher C., Bockow B., Markenson J., Ko A. et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford). 2002;41(9):1052–1061. doi: 10.1093/rheumatology/41.9.1052.Gottesdiener K., Schnitzer T., Fisher C., Bockow B., Markenson J., Ko A. et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford). 2002;41(9):1052–1061. doi: 10.1093/rheumatology/41.9.1052.Moss P., Benson H.A.E., Will R., Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017;25(11):1781– 1791. doi: 10.1016/j.joca.2017.07.009.Moss P., Benson H.A.E., Will R., Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017;25(11):1781– 1791. doi: 10.1016/j.joca.2017.07.009.Smith S.R., Deshpande B.R., Collins J.E., Katz J.N., Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962–972. doi: 10.1016/j.joca.2016.01.135.Smith S.R., Deshpande B.R., Collins J.E., Katz J.N., Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962–972. doi: 10.1016/j.joca.2016.01.135.Jung S.Y., Jang E.J., Nam S.W., Kwon H.H., Im S.G., Kim D. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018;28(6):1021–1028. doi: 10.1080/14397595.2018.1439694.Jung S.Y., Jang E.J., Nam S.W., Kwon H.H., Im S.G., Kim D. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018;28(6):1021–1028. doi: 10.1080/14397595.2018.1439694.Rasmussen S. NSAIDs are superior to paracetamol for osteoarthritic pain and function in a network meta-analysis. BMJ Evid Based Med. 2018;23(1):40–41. doi: 10.1136/ebmed-2017110878.Rasmussen S. NSAIDs are superior to paracetamol for osteoarthritic pain and function in a network meta-analysis. BMJ Evid Based Med. 2018;23(1):40–41. doi: 10.1136/ebmed-2017110878.Baraf H.S., Fuentealba C., Greenwald M., Brzezicki J., O’Brien K., Soffer B. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol. 2007;34(2):408–420. Available at: https://pubmed.ncbi.nlm.nih.gov/17304660-gastrointestinal-side-effectsof-etoricoxib-in-patients-with-osteoarthritisresults-of-the-etoricoxib-versus-diclofenacsodium-gastrointestinal-tolerability-andeffectiveness-edge-trial/Baraf H.S., Fuentealba C., Greenwald M., Brzezicki J., O’Brien K., Soffer B. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol. 2007;34(2):408–420. Available at: https://pubmed.ncbi.nlm.nih.gov/17304660-gastrointestinal-side-effectsof-etoricoxib-in-patients-with-osteoarthritisresults-of-the-etoricoxib-versus-diclofenacsodium-gastrointestinal-tolerability-andeffectiveness-edge-trial/Krueger K., Lino L., Dore R., Radominski S., Zhang Y., Kaur A. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008;67(3):315–322. doi: 10.1136/ard.2007.082388.Krueger K., Lino L., Dore R., Radominski S., Zhang Y., Kaur A. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008;67(3):315–322. doi: 10.1136/ard.2007.082388.Ramey D.R., Watson D.J., Yu C., Bolognese J.A., Curtis S.P., Reicin A.S. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005;21(5):715–722. doi: 10.1185/030079905X43686.Ramey D.R., Watson D.J., Yu C., Bolognese J.A., Curtis S.P., Reicin A.S. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005;21(5):715–722. doi: 10.1185/030079905X43686.Laine L., Curtis S.P., Cryer B., Kaur A., Cannon C.P. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–473. doi: 10.1016/S0140-6736(07)60234-7.Laine L., Curtis S.P., Cryer B., Kaur A., Cannon C.P. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–473. doi: 10.1016/S0140-6736(07)60234-7.Laine L., Curtis S.P., Langman M., Jensen D.M., Cryer B., Kaur A., Canon C.P. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135(5):1517–1525. doi: 10.1053/j.gastro.2008.07.067.Laine L., Curtis S.P., Langman M., Jensen D.M., Cryer B., Kaur A., Canon C.P. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135(5):1517–1525. doi: 10.1053/j.gastro.2008.07.067.Yang M., Wang H.T., Zhao M., Meng W-B., Ou J.Q., Zou B, Lei P-G. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015;94(40):e1592. doi: 10.1097/MD.0000000000001592.Yang M., Wang H.T., Zhao M., Meng W-B., Ou J.Q., Zou B, Lei P-G. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015;94(40):e1592. doi: 10.1097/MD.0000000000001592.Ray W.A., Varas-Lorenzo C., Chung C.P., Castellsague J., Murray K.T., Stein M. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155–163. doi: 10.1161/CIRCOUTCOMES.108.805689.Ray W.A., Varas-Lorenzo C., Chung C.P., Castellsague J., Murray K.T., Stein M. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155–163. doi: 10.1161/CIRCOUTCOMES.108.805689.Krum H., Swergold G., Curtis S.P., Kaur A., Wang H., Smugar S.S. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27(4):886–893. doi: 10.1097/HJH.0b013e328325d831.Krum H., Swergold G., Curtis S.P., Kaur A., Wang H., Smugar S.S. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27(4):886–893. doi: 10.1097/HJH.0b013e328325d831.Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–1781. doi: 10.1016/s0140-6736(06)69666-9.Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771–1781. doi: 10.1016/s0140-6736(06)69666-9.Curtis S.P., Ng J., Yu Q., Shingo S., Bergman G., McCormick C.L., Reicin A.S. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther. 2004;26(1):70–83. doi: 10.1016/S0149-2918(04)90007-0.Curtis S.P., Ng J., Yu Q., Shingo S., Bergman G., McCormick C.L., Reicin A.S. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther. 2004;26(1):70–83. doi: 10.1016/S0149-2918(04)90007-0.Masclee G.M.C., Straatman H., Arfè A., Castellsague J., Garbe E., Herings R. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018;13(11):e0204746. doi: 10.1371/journal.pone.0204746.Masclee G.M.C., Straatman H., Arfè A., Castellsague J., Garbe E., Herings R. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018;13(11):e0204746. doi: 10.1371/journal.pone.0204746.Arfè A., Scotti L., Varas-Lorenzo C., Nicotra F., Zambon A., Kollhorst B. et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested casecontrol study. BMJ. 2016;354:i4857. doi: 10.1136/bmj.i4857.Arfè A., Scotti L., Varas-Lorenzo C., Nicotra F., Zambon A., Kollhorst B. et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested casecontrol study. BMJ. 2016;354:i4857. doi: 10.1136/bmj.i4857.Schink T., Kollhorst B., Varas Lorenzo C., Arfè A., Herings R., Lucchi S. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018;13(9):e0203362. doi: 10.1371/journal.pone.0203362.Schink T., Kollhorst B., Varas Lorenzo C., Arfè A., Herings R., Lucchi S. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018;13(9):e0203362. doi: 10.1371/journal.pone.0203362.Huang W.-N., Tso T.K. Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly. Bosn J Basic Med Sci. 2018;18(1):87–94. doi: 10.17305/bjbms.2017.2214.Huang W.-N., Tso T.K. Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly. Bosn J Basic Med Sci. 2018;18(1):87–94. doi: 10.17305/bjbms.2017.2214.Сивордова Л.Е., Заводовский Б.В., Полякова Ю.В., Ахвердян Ю.Р. Доказательства целесообразности применения эторикоксиба в терапии остеоартроза у пациентов старших возрастных групп. Успехи геронтологии. 2016;29(2):286–290. Режим доступа: http://www.gersociety.ru/netcat_files/userfiles/10/AG_2016-29-02.pdf.Sivordova L.E., Zavodovsky B.V., Polyakova J.V., Akhverdyan Y.R. Evidence of feasibility etoricoxib therapy in osteoarthritis in elderly patients. Uspekhi gerontologii = Advances in gerontology. 2016;29(2):286–290. (In Russ.) Available at: http://www.gersociety.ru/netcat_files/userfiles/10/AG_2016-29-02.pdf.Takemoto J.K., Reynolds J.K., Remsberg C.M., Vega-Villa K.R., Davies N.M. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703–720. doi: 10.2165/00003088-200847110-00002.Takemoto J.K., Reynolds J.K., Remsberg C.M., Vega-Villa K.R., Davies N.M. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703–720. doi: 10.2165/00003088-200847110-00002.

The authors declare that there are no conflicts of interest present.